2852 Kelvin Avenue
717 articles about Masimo Corporation
Federal Court Rules for Masimo in Suit Against Former Engineer for Unlawful Theft of Company’s Pulse Oximeter Trade Secrets
The United States District Court for the Central District of California has ruled that a former Masimo engineer misappropriated trade secrets related to Masimo’s pulse oximetry technology.
Masimo announced that its management will participate in the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 at 1:50 p.m. Eastern Time.
Masimo announced its financial results for the third quarter of 2022, ended October 1, 2022.
Masimo (NASDAQ: MASI) will release third quarter 2022 financial results for the period ended October 1, 2022, after the market closes on Tuesday, November 8, 2022.
Masimo announced the appointment of Blair Tripodi as Chief Operating Officer for the Masimo Consumer division, effective immediately.
Masimo announced its financial results for the second quarter of 2022, ended July 2, 2022.
Masimo (NASDAQ: MASI) will release second quarter 2022 financial results for the period ended July 2, 2022, after the market closes on Tuesday, August 9, 2022.
Randomized Controlled Study Finds Masimo SedLine® Brain Function Monitoring Can Help Guide Anesthesia in Children Undergoing Minor Surgery
Masimo (NASDAQ: MASI) today announced the findings of a randomized, controlled trial published in the Journal of Clinical Anesthesia in which Dr. Melody H.Y. Long and colleagues from the KK Women’s and Children’s Hospital in Singapore evaluated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine® brain function monitoring, to reduce the amount of the drug sevoflurane needed to maintain anesthesia in pediatric patients undergoing minor surgery.
New Study Finds That Masimo PVi® May Be Useful in Helping ER Doctors Determine the Severity of Asthma Attacks in Pediatric Patients
Masimo announced the findings of a retrospective study published in the American Journal of Emergency Medicine in which Dr. Gülsah Demir and colleagues at Tepecik Research and Training Hospital in Izmir, Turkey investigated the potential ability of Masimo PVi® to guide emergency room triage decisions for pediatric patients with signs of obstructive respiratory disease, such as an asthma attack.
Masimo announced its financial results for the first quarter of 2022, ended April 2, 2022.
Masimo SedLine® Brain Function Monitoring Reduced the Use of Anesthetic Agents and Opioids in a Study on Patients Undergoing Cardiac Surgery
Masimo (NASDAQ: MASI) today announced the findings of a retrospective study published in the Journal of Cardiothoracic and Vascular Anesthesia.
New JAMA Article Highlights the Outcome and Safety Benefits of Remote Patient Monitoring During the Pandemic and Beyond
Masimo (NASDAQ: MASI) today announced the findings of a Viewpoint article recently published in the Journal of the American Medical Association (JAMA) which highlighted the benefits of remote home patient monitoring, reporting in part on research that used Masimo SafetyNet®.
Masimo Announces Certain Preliminary First Quarter 2022 Financial Results and Reaffirms Full-Year 2022 Revenue Guidance
Masimo Corporation announced certain preliminary financial results for the first quarter ending April 2, 2022 and reaffirmed its full-year 2022 revenue guidance.
New Study Finds That Noninvasive and Continuous Hemoglobin Improved Transfusion Management and Outcomes in Pediatric Patients
Masimo announced the findings of a retrospective study published in the Journal of Clinical Monitoring and Computing in which Dr. Ayten Saracoglu and colleagues at Marmara University in Istanbul, Turkey evaluated the impact of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® on perioperative transfusion management and postoperative patient outcomes on pediatric patients undergoing fronto-orbital advancement surgery.
Masimo announced a major expansion of Masimo Patient SafetyNet™, its premier hospital remote patient monitoring and clinician notification platform, with the addition of secure telehealth capabilities – making an already powerful solution even more versatile and comprehensive.
Masimo Announces FDA Clearance of Pediatric Indication for SedLine® Brain Function Monitoring and the SedLine Pediatric EEG Sensor
Masimo (NASDAQ: MASI) announced today the FDA clearance of SedLine® brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor.
Sound United, LLC, a leading innovator of premium, high-performance audio products for consumers around the world, announced that it has entered into a definitive agreement to be acquired by Masimo Corporation .
Masimo Reports Fourth Quarter and Full-Year 2021 Financial Results and Announces Agreement to Acquire Sound United
Masimo announced its financial results for the fourth quarter and full-year ended January 1, 2022.
Masimo and Temple Health announced that Temple University Hospital, a 722-bed academic medical center located in Philadelphia, is expanding its use of Masimo technologies with Centroid™, an advanced wireless patient position, orientation, activity, and respiration rate sensor, at 100 beds across its ICU units.
Restrospective Study Finds That Masimo SET® Pulse Oximetry Has No Difference in Accuracy or Bias Between Black People and White People
Masimo (NASDAQ: MASI) today announced the findings of an abstract presented last Saturday at the Society for Technology in Anesthesia 2022 Annual Meeting, which reviewed retrospective pulse oximetry data and concluded that there was no clinically significant bias based on ethnicity for black and white volunteer subjects monitored with Masimo SET® pulse oximetry and RD SET® sensors.